Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...
A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening ...
Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...
Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...
There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role. He will be replaced as head of AbbVie ...
TAK-721 is one of 12 "Wave1" pipeline drug candidates that have been held up by Takeda as potential blockbuster products, because they are either best-in-class or first-in-class therapies. The ...
3382.T Seven & i Holdings Co., Ltd.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results